Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15232
UPID:
MATN3_HUMAN
Alternative names:
-
Alternative UPACC:
O15232; B2CPU0; Q4ZG02
Background:
Matrilin-3, encoded by the gene with accession number O15232, is a pivotal component of the extracellular matrix in cartilage. It plays a crucial role in the formation of extracellular filamentous networks, essential for maintaining the structural integrity and function of cartilage.
Therapeutic significance:
The protein is implicated in several skeletal disorders, including Multiple epiphyseal dysplasia 5, characterized by irregular ossification and early-onset osteoarthritis, and Spondyloepimetaphyseal dysplasia, Borochowitz-Cormier-Daire type, marked by disproportionate dwarfism and skeletal abnormalities. Additionally, it is associated with Osteoarthritis 2, a degenerative joint disease. Understanding the role of Matrilin-3 could open doors to potential therapeutic strategies for these conditions.